

**ISPOR Student Presentations  
19th Annual European Congress**

**BREAKOUT SESSION: MONDAY, 31 OCTOBER 2016, 14:15 - 15:15  
P2: STUDIES ON HTA APPROACHES**

HT4	IMPLEMENTATION OF CONDITIONAL REIMBURSEMENT SCHEMES IN HTA PRACTICE: EXPERIENCES FROM THE NETHERLANDS	Amr Makady	The National Healthcare Institute (ZIN)
-----	---	------------	---

**BREAKOUT SESSION: MONDAY, 31 OCTOBER 2016, 14:15 - 15:15  
P3: UTILITY STUDIES**

UT2	A META REGRESSION ANALYSIS OF UTILITY WEIGHTS FOR BREAST CANCER	Ji Ryoung Gong	Ewha Womans University
UT4	MAPPING QUALITY OF LIFE SCORES FROM FACT-G, FAACT AND FACIT-F ONTO PREFERENCE-BASED UTILITIES USING THE 5-LEVEL VERSION OF EQ-5D QUESTIONNAIRE	Michela Meregaglia	Bocconi University

**BREAKOUT SESSION: MONDAY, 31 OCTOBER 2016, 15:45 - 16:45  
P4: CARDIOVASCULAR OUTCOMES RESEARCH STUDIES**

CV4	ARE COMPONENT ENDPOINTS EQUAL? A STUDY INTO THE PRACTICE OF COMPOSITE END POINTS IN CLINICAL TRIALS	J van Til	University Twente
-----	---	-----------	-------------------

**BREAKOUT SESSION: MONDAY, 31 OCTOBER 2016, 15:45 - 16:45  
P5: PRICING POLICY STUDIES**

PR4	THE DETERMINANTS OF INNOVATIVE DRUGS PRICES: THE CASE OF ONCOLOGY DRUGS, COMPARATIVE ANALYSIS	Amine Aissaoui	Paris Dauphine University, PSL
-----	---	----------------	--------------------------------

**BREAKOUT SESSION: MONDAY, 31 OCTOBER 2016, 17:00 - 18:00  
P6: MEDICATION ADHERENCE STUDIES**

AD2	A FRAMEWORK FOR MEASURING ADHERENCE TO MULTIPLE MEDICATIONS	Priti Pednekar	University of the Sciences
-----	---	----------------	----------------------------

**BREAKOUT SESSION: TUESDAY, 1 NOVEMBER 2016, 8:45 - 9:45  
P7: NEUROLOGICAL DISORDERS STUDIES**

ND1	BURDEN AND WORK PRODUCTIVITY LOSS IMPAIRMENT FROM PROVIDING CARE TO ALZHEIMER'S DISEASE PATIENTS	Xiaohan Hu	Merck & Co. Inc
-----	--	------------	-----------------

**BREAKOUT SESSION: TUESDAY, 1 NOVEMBER 2016, 8:45 - 9:45  
P8: PATIENT PREFERENCE STUDIES**

PP1	NINE TESTS FOR ASSESING VALIDITY OF A DISCRETE-CHOICE EXPERIMENT	Ellen M Janssen	Johns Hopkins Bloomberg School of Public Health
-----	--	-----------------	---

**BREAKOUT SESSION: TUESDAY, 1 NOVEMBER 2016, 15:15 - 16:15  
P11: DATABASE USE IN OUTCOMES RESEARCH STUDIES**

DB4	USE OF DATA-MINING TO PERFORM A REAL WORLD COST ANALYSIS OF HER2-POSITIVE BREAST CANCER IN IRAN	Amir Ansaripour	Erasmus University Rotterdam
-----	---	-----------------	------------------------------

**RESEARCH POSTER PRESENTATIONS - SESSION I: 8:45 - 14:15**  
**INDIVIDUAL'S HEALTH**

PIH11	AVAILABILITY AND COSTS OF PEDIATRIC FORMULATIONS IN INDIA : A CASE STUDY	Himanshu Tayal	Maulana Azad Medical college
PIH12	ECONOMIC EVALUATION OF RFSH AND HP-HMG FOR INFERTILITY TREATMENT IN BRAZIL	Paulo V S Souza	Merck
PIH13	INFERTILITY TREATMENT OF WOMEN OVER AGE 35 IN BRAZIL: AN ECONOMIC EVALUATION OF RECOMBINANT VS. URINARY GONADOTROPINS	Paulo V S Souza	Merck
PIH14	EVALUATING THE ECONOMIC IMPACT OF POTENTIALLY INAPPROPRIATE PRESCRIBING IN OLDER PEOPLE IN IRELAND USING A MARKOV MODELLING APPROACH	Frank Moriarty	Royal College of Surgeons in Ireland
PIH15	COST IMPLICATIONS OF INAPPROPRIATE PRESCRIBING OF ANTI-MALARIAL THERAPY FOR TREATMENT OF UNDIFFERENTIATED FEBRILE ILLNESS AMONG ELDERLY	Vineetha Bharathan Menon	JSS Hospital
PIH16	ANALYSIS OF REAL DATA FOR TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY (NVP) IN UKRAINE	Natalia Maksymovych	Danylo Halytsky Lviv National Medical University
PIH22	VAGINAL BIRTH AFTER CAESAREAN VERSUS ELECTIVE REPEAT CAESAREAN DELIVERY IN FOUR EUROPEAN COUNTRIES: A COST-UTILITY ANALYSIS	Maaïke Fobelets	Vrije Universiteit Brussel
PIH26	TRANSLATION AND VALIDATION OF CONDITION-SPECIFIC QUALITY OF LIFE PFDI-20 AND PFIQ-7 QUESTIONNAIRES FOR WOMEN WITH PELVIC FLOOR DYSFUNCTION IN THE NORWEGIAN CONTEXT	Catherine J Planke Teig	Flinders University
PIH29	SELF-EFFICACY AND HEALTH BEHAVIORS IMPACT QUALITY OF LIFE OF ELDERLY ALONG EASTERN SEA COAST OF THAILAND 2015	Titinun Auamnoy	Burapha University
PIH38	PREVALENCE OF POTENTIALLY INAPPROPRIATE PRESCRIBING IN CENTRAL NERVOUS SYSTEM AND PSYCHOTROPIC DRUGS FOR THE KOREAN ELDERLY: A CROSS-SECTIONAL STUDY USING THE NATIONAL HEALTH INSURANCE CLAIMS DATABASE	Hyeonseok Cho	Yonsei University

**RESEARCH POSTER PRESENTATIONS - SESSION I: 8:45 - 14:15**  
**INFECTION**

PIN1	THE CHICKENPOX COMPLICATIONS AND FINANCIAL BURDEN IN HEALTHY CHILDREN AND WITH UNDERLYING A COMORBIDITY DURING THE PRE VACCINE AND POST VACCINE ERA IN A UNIVERSITY HOSPITAL	Ayşe Büyükcım	Hacettepe University Faculty of Medicine, Department of Pediatric Infectious Diseases
------	--	---------------	---

PIN11	SUSCEPTIBILITY PATTERN OF PSEUDOMONAS AERUGINOSA ISOLATES TO CARBAPENEM ANTIBIOTICS	Maria Zubair	Peshawar Medical and Dental College
PIN20	BUDGET IMPACT ANALYSIS OF INCLUDING A PENTAVALENT (HIB-HBV-DTP) VACCINE IN THE NATIONAL CHILDHOOD IMMUNIZATION SCHEDULE OF IRAN	Fatemeh Teimouri	Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran University of Medical Sciences
PIN22	HEALTH CARE COSTS, LENGTH OF STAY AND MORTALITY OF CARBAPENEM RESISTANCE GRAM-NEGATIVE BACTEREMIA	Mehmet Ceyhan	Hacettepe University Pediatric Infectious Disease
PIN33	COST ASSESSMENT OF ANTIBIOTICS USE IN A HOSPITAL IN THE DOMINICAN REPUBLIC	Maria Laura Silva	University of Bordeaux
PIN47	COST-EFFECTIVENESS OF GRAZOPREXIL / ELBASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS	T. Joseph Mattingly II	University of Maryland School of Pharmacy
PIN52	INCLUSION OF COSTS AND EFFECTS RELATED TO TOXICITY/SAFETY IN COST - EFFECTIVENESS ANALYSIS; AN ILLUSTRATION FOR INFLUENZA VACCINES	Tanja Fens	University of Groningen
PIN78	IMPAIRED QUALITY OF LIFE AFTER CHIKUNGUNYA VIRUS INFECTION: A 12-MONTHS FOLLOW-UP STUDY OF ITS CHRONIC INFLAMMATORY RHEUMATISM IN LA VIRGINIA, RISARALDA, COLOMBIA	Victor Manuel Restrepo-Posada	Universidad Tecnológica de Pereira
PIN84	GENERAL PRACTITIONERS PERCEPTIONS ABOUT FINANCIAL AND NON-FINANCIAL INCENTIVES TO IMPROVE INFLUENZA VACCINATION COVERAGE RATES IN FRANCE	Maria Laura Silva	University of Bordeaux
PIN89	ESTIMATING THE VALUE OF A NEW ANTIBIOTIC: A NOVEL APPROACH USING ESBL AS A CASE STUDY	Kirk Geale	Umeå University
PIN9	THERAPEUTIC INDICATION OF LYOPHILIZED HYDROCORTISONE TO THE TREATMENT OF TRICHINOSIS WITH NEUROLOGICAL AND / OR MYOCARDIAL INVOLVEMENT	MG Pitta	Universidade Federal de Pernambuco
PIN97	THE PREVALENCE OF NOSOCOMIAL INFECTIONS IN KARAGANDA (KAZAKHSTAN) DURING 2011-2015	E. Kultanova	Karaganda State Medical University

**RESEARCH POSTER PRESENTATIONS - SESSION I: 8:45 - 14:15  
NEUROLOGICAL DISORDERS**

PND1	META-ANALYSIS OF NEWER ANTI-EPILEPTIC DRUGS FOR TREATMENT OF PARTIAL EPILEPSY IN CHILDREN	Nurul Ain Mohd Tahir	University of Newcastle
PND23	CENTRAL NERVOUS SYSTEM, MULTIPLE SCLEROSIS AND SOCIAL SECURITY: THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM PENSIONS IN ITALY	Simone Russo	University of Rome "Sapienza"
PND33	USE OF ENZYME INHIBITION WITH RITONAVIR TO IMPROVE THE COST-EFFECTIVENESS OF IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS (CF) IN IRELAND <b>** WITHDRAWN **</b>	Anne Marie Liddy	Trinity College Dublin

PND39	COST EFFECTIVENESS OF IVACAFTOR AND LUMACAFTOR COMBINATION FOR THE TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS IN THE UNITED STATES	Dolly Sharma	University of Illinois at Chicago
PND65	QUALITY OF LIFE IN RELAPSING REMMITING MULTIPLE SCLEROSIS: INFLUENCE OF INTERFERON BETA-1A (AVONEX AND CINNOVEX) TREATMENT	rahil Sadat Shahtaheri	Tehran University of Medical Science
PND72	FUTURE INNOVATIVE THERAPIES FOR PARKINSON'S DISEASE MAY QUESTION SUSTAINABILITY OF OUR HEALTH CARE SYSTEM	Eve Hanna	Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université
PND73	ECONOMIC AND HUMANISTIC BENEFITS OF MAINTAINING COGNITIVE IMPAIRMENT PATIENTS IN THE EARLY STAGE	Xiaohan Hu	Merck & Co. Inc

**RESEARCH POSTER PRESENTATIONS - SESSION I: 8:45 - 14:15**  
**RESEARCH ON METHODS**

PRM100	SYSTEMATIC REVIEW OF COST-EFFECTIVENESS MODELS IN DIABETES FOR INSULIN ANALOGUES	Chin Hui Ng	Universiti sains malaysia
PRM105	DIVERSITY IN ECONOMIC EVALUATIONS HAMPERS VALID DECISION-MAKING IN METASTATIC COLORECTAL CANCER	Gerrit L. Merkens	Utrecht University
PRM110	A REVIEW ON THE CURRENT STATUS OF HEALTH ECONOMIC MODELING IN PERSONALIZED MEDICINE	Koen Degeling	University of Twente
PRM126	DEFINING REAL-WORLD PRODUCT PERFORMANCE USING SURVIVAL ANALYSIS AND SUPERVISED MACHINE LEARNING	Tine Geldof	KU Leuven
PRM133	GENERALISING RESULTS FROM COST-EFFECTIVENESS ANALYSIS: A COMPARISON OF METHODS TO ACCOUNT FOR COVARIATES	Theodoros Mantopoulos	University of Bristol
PRM141	DEVELOPING A CONCEPTUAL FRAMEWORK AND A TOOL FOR MEASURING ABSORPTIVE CAPACITY IN PHARMACEUTICAL COMPANIES	Ehsan Sanati	Tehran University of Medical Sciences
PRM145	USING ACOUSTIC SIMULATIONS OF HEARING LOSS TO DESCRIBE HEALTH STATES: ARE THEY FEASIBLE AND RELIABLE TO USE?	Natalie J Williams	NIHR Nottingham Hearing Biomedical Research Unit
PRM16	A NEW MODEL TO IDENTIFY MULTIVARIATE CAUSES OF HIGH COST IN PATIENT WITH ADVANCED LIVER DISEASE	Jose Antonio Turri	Sao Paulo Medical School - Sao Paulo University
PRM161	USING ORTHOGONAL DESIGN IN SELECTING HEALTH STATES FOR THE CONSTRUCTION OF EQ-5D-3L VALUE SET	Zhihao Yang	Erasmus University Rotterdam
PRM17	APPLICATION OF A VALUE FRAMEWORK-BASED ON MULTIPLE CRITERIA DECISION-ANALYSIS IN THE CONTEXT OF HEALTH-TECHNOLOGY ASSESSMENT: A SERIES OF CASE STUDIES WITH DECISION MAKERS-ACROSS EUROPEAN COUNTRIES <b>** WITHDRAWN **</b>	Aris Angelis	London School of Economics and Political Science

PRM178	USING ANALYTIC HIERARCHY PROCESS TO WEIGHT PATIENT-RELEVANT OUTCOMES IN THE TREATMENT OF PSORIASIS FOR CALCULATING THE PATIENT BENEFIT INDEX	Mandy Gutknecht	University Medical Center Hamburg-Eppendorf
PRM180	MULTIPLE MYELOMA AND HEALTH-RELATED QUALITY OF LIFE FROM EQ-5D AND EORTC: A SYSTEMATIC LITERATURE REVIEW	Vjollca Qerimi	UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, Skopje, Macedonia
PRM182	EUROQOL TO ASSESS THE QUALITY OF LIFE WITH SMARTPHONE	Andrey Vorobiev	Russian Society for Pharmacoeconomics and Outcomes Research
PRM189	VIEWPOINTS OF THALASSAEMIA PATIENTS ON THE COMBINATION OF TRADITIONAL & COMPLEMENTARY MEDICINE (T&CM) WITH THE CONVENTIONAL THALASSAEMIA TREATMENT: A QUALITATIVE UNDERSTANDING APPROACH	wan Ismahanisa Ismail	Faculty of Health Sciences University Technology MARA
PRM218	COMPARISON BETWEEN CANCER DRUGS ASSESSMENT IN PORTUGAL AND UNITED KINGDOM	Sofia Carmo	ISCTE-IUL
PRM28	REVIEW OF METHODS FOR COMBINING INDIVIDUAL AND AGGREGATE DATA IN A META-ANALYSIS	Raissa Kapso Kapnang	National School For Statistics and Information Analysis (ENSAI)
PRM39	EVALUATING THERAPEUTIC TREATMENTS FOR PSORIATIC ARTHRITIS: CAN WE MAKE BETTER USE OF PATIENT DATA REGISTRIES?	Matthew James Walton	University of York
PRM40	CHALLENGES IN ECONOMIC EVALUATIONS CONDUCTED ALONGSIDE CLINICAL TRIALS OF SCHIZOPHRENIA: THE CASE OF THE ACTIONS STUDY	Noemi Kiss	Medical University of Vienna
PRM45	HOW TIME AND SEVERITY INCREASES THE OVERALL COST AND RESOURCE UTILIZATION OF PATIENT WITH SEVERE LIVER DISEASE. MAIN BURDENS AND CONSEQUENCES TO HEALTH SYSTEM	Jose Antonio Turri	Sao Paulo Medical School - Sao Paulo University
PRM49	THE COST-EFFECTIVENESS OF BLUE-LIGHT THERAPY VS FIXED COMBINATION OF CALCIPOTRIOL AND BETAMETHASONE DIPROPIONATE GEL IN THE TREATMENT OF MILD-TO-MODERATE PSORIASIS	Amir Ansaripour	Erasmus University Rotterdam
PRM54	APPROPRIATE ANALYSIS OF THE ADDITIONAL COSTS OF ANTIBIOTIC RESISTANCE: THE IMPACT OF DIFFERENT BIASES <b>** WITHDRAWN **</b>	Thomas Heister	University of Freiburg
PRM65	THE USE OF ADMINISTRATIVE DATA TO DETERMINE PREVALENCE AND INCIDENCE OF COPD: A SYSTEMATIC REVIEW	Sasa Rajsic	UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment
PRM67	MEASURES TAKEN BY THE ROMANIAN MINISTRY OF HEALTH FOR BETTER ACCESS TO ANTI-EGFR DRUGS	Adina Turcu-Stiolică	University of Medicine and Pharmacy

PRM71	PREDICTION OF COSTS ASSOCIATED WITH THE HOSPITAL MANAGEMENT OF HIV PATIENTS IN FRANCE USING AN ADVANCED DATA MINING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE	Martin Prodel	HEVA
PRM74	EXPERT ELICITATION: CAN VARIATION IN ELICITED DISTRIBUTIONS BE EXPLAINED BY EXPERT HETEROGENEITY?	Dina Jankovic	University of York
PRM79	MISSING THE VALUE OF HERD IMMUNITY IN COST-EFFECTIVENESS ANALYSIS. A SYSTEMATIC REVIEW	LN Nymark	aarhus university
PRM9	GUIDELINES FOR TRANSLATION AND CROSS-CULTURAL ADAPTATION OF NON-TECHNICAL SKILLS RATING INSTRUMENTS	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PRM97	ACCOUNTING FOR THE IMPERFECT EXTERNAL VALIDITY OF DISCRETE CHOICE EXPERIMENTS WHEN PREDICTING DEMAND	Matthew Quaife	London School of Hygiene and Tropical Medicine

**RESEARCH POSTER PRESENTATIONS - SESSION II: 15:45 - 19:45  
GASTROINTESTINAL DISORDERS**

PGI16	5 YEAR AND LONG-TERM BUDGET IMPACT ANALYSIS OF NEW HEPATITIS C THERAPIES FROM A PAYER PERSPECTIVE IN SWITZERLAND	Anita Schnyder	Zürcher Hochschule für Angewandte Wissenschaften
-------	--	----------------	--

**RESEARCH POSTER PRESENTATIONS - SESSION II: 15:45 - 19:45  
HEALTH CARE USE & POLICY STUDIES**

PHP10	ROLE OF GENETIC VARIATION IN TYPE-REPEATS OF HISTIDINE RICH PROTEIN-2- GENE IN ALTERING THE PERFORMANCE OF- MALARIA RAPID DETECTION KIT IN GLOBAL- CONTEXT <b>** WITHDRAWN **</b>	Prabhat Ranjan	Sanjay Gandhi Postgraduate Institute of Medical Sciences
PHP114	A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION ALONGSIDE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN	Thi Thu Ha Tran	University of Tsukuba
PHP117	DOES HOSPITAL AT HOME NEED A NEW FUNDING FOR ORAL ANTI-CANCER DRUGS ?	Afsaneh Gohari	Hospital at Home, Assistance Publique- Hôpitaux de Paris (AP-HP)
PHP133	TAKING IN ACCOUNT RESEARCH AND DEVELOPMENT EXPENDITURES TO DETERMINE PRICES OF MEDICINES IN FRANCE: A REALISTIC ALTERNATIVE CHOICE?	Charlotte Masia	Université Paris-Dauphine
PHP136	BIG DATA IN HEALTHCARE - OPPORTUNITIES AND CHALLENGES	Florian Leppert	School of Public Health, Bielefeld University
PHP143	A STUDY EVALUATING LIVING ORGAN DONORS IN KIDNEY AND LIVER TRANSPLANTATION	Emily Zacherle	University of North Carolina at Charlotte
PHP177	PSYCHOMETRIC TESTING OF THE FINNISH VERSION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PHP183	HOW TO SELECT THE BEST COMPARATOR? AN INTERNATIONAL ECONOMIC EVALUATION GUIDELINES COMPARISON	Sonia Ziouani	Univ Paris-Sud, Faculty of Pharmacy, GRADES

PHP186	HOW TO DEFINE RELEVANT COMPARATORS IN FRANCE? AN ANALYSIS OF THE ECONOMIC EVALUATIONS SUBMITTED BY MANUFACTURERS AND REVIEWED BY THE ECONOMIC COMMITTEE (CEESP) OF THE FRENCH NATIONAL HEALTH AUTHORITY	Sonia Ziouani	Univ Paris-Sud, Faculty of Pharmacy, GRADES
PHP188	PSYCHOMETRIC PROPERTIES OF THE FINNISH VERSION OF THE LOCOMOTOR CAPABILITIES INDEX-5	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PHP195	PSYCHOMETRIC PROPERTIES OF THE FINNISH VERSION OF THE LOWER EXTREMITY FUNCTIONAL SCALE AMONG FOOT AND ANKLE PATIENTS	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PHP211	LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE VISUAL ANALOGUE SCALE FOOT AND ANKLE INSTRUMENT	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PHP22	THE SHIFT FROM A COMPASSIONATE DRUG USE TO THE COMMON MARKET-ACCESS PROCESS: AN INFLATIONARY NO MAN'S LAND?	Anais Loubiere	General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP)
PHP221	ASSESSMENT OF PATIENT NEED DURING HOSPITALIZATION BY USING NEQ (NEED EVALUATION QUESTIONNAIRE) IN TERTIARY CARE HOSPITALS, QUETTA, PAKISTAN	Noman Haq	University of Balochistan
PHP227	INFLUENCING FACTORS ON KNOWLEDGE, ATTITUDE AND BEHAVIOUR TOWARDS ANTIBIOTIC USAGE AMONG ADULTS IN HO CHI MINH CITY, VIET NAM	Thao Nguyen Ngo	University of Medicine and Pharmacy, Ho Chi Minh City
PHP23	FUNDING EXPENSIVE DRUGS IN HOSPITALS: WHERE IS FRANCE GOING?	Romain Cousseau	General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP)
PHP230	RECONSTRUCTION OF MAJOR LOWER-EXTREMITY AMPUTATION STUMP WITH A FREE LATISSIMUS DORSI FLAP	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PHP247	ASSESSMENT OF WILLINGNESS TO PAY FOR CONSULTATION AND DIAGNOSTIC SERVICES IN SHEIKH KHALIFA BIN ZAYYED AL-NAYYAN MEDICAL COMPLEX, QUETTA	Noman Haq	University of Balochistan
PHP249	LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE MODIFIED MOBILITY SECTION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PHP260	AUTOMATION OF HOSPITAL MEDICATION DISTRIBUTION SYSTEMS IN THE US	Ebtissam Mohammad Badawoud	MCPHS University
PHP261	ASSESSMENT OF KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) OF PHARMACIST REGARDING ADVERSE DRUG REACTION (ADRS) AND PHARMACOVIGILANCE IN PUBLIC HOSPITALS QUETTA	Noman Haq	University of Balochistan
PHP263	EXPLORING THE SOCIOECONOMIC IMPACT OF POST APPROVAL CHANGE REQUIREMENTS FOR VACCINES	Aris Angelis	London School of Economics and Political Science
PHP268	ECONOMIC IMPACT OF ADVERSE DRUG REACTIONS: A PUBMED-BASED STUDY <b>** WITHDRAWN **</b>	Bhavana Bhat	Manipal University



PHP270	ATTRIBUTES DEFINING PATIENT ENGAGEMENT AND CENTEREDNESS IN HEALTH CARE RESEARCH AND PRACTICE: A FRAMEWORK DEVELOPED BY THE ISPOR PATIENT-CENTERED SPECIAL INTEREST GROUP	Maya L. Hanna	School of Pharmacy, University of Maryland
PHP272	ADVANCED THERAPIES: WIDENING THE GAP BETWEEN PAYERS AND REGULATORS	Eve Hanna	Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université
PHP277	CONCORDANCE OF HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS OF DIABETES, HEPATITIS, ONCOLOGY AND EPILEPSY PHARMACEUTICAL PRODUCTS BY FIVE AGENCIES WITHIN EUROPE: AN INTERRATER RELIABILITY AND ASSOCIATION ANALYSIS	Issifu Abugri	Cardiff University in collaboration with Hochschule Fresenius
PHP296	SWEDISH PERSPECTIVE ON HEALTH TECHNOLOGY ASSESSMENTS WITH INCREMENTALLY LOWER COSTS AND EFFECTS	Kirk Geale	Umeå University
PHP307	IMPLEMENTATION OF PROCESSES TO ESTABLISHING A HTA UNIT IN CZECH HOSPITAL ENVIRONMENT	Martin Zavadil	Motol University Hospital
PHP338	SIMILARITIES AND DIFFERENCES OF RISK SHARING ARRANGEMENTS IN AUSTRALIA, UNITED KINGDOM, ITALY, AND KOREA	Sohyun Kim	Ewha Womans University
PHP346	A NEW COVERAGE WITH EVIDENCE DEVELOPMENT DEDICATED TO INNOVATIVE MEDICAL BIOLOGY AND PATHOLOGICAL ANATOMY AND CYTOLOGY PROCEDURES IN FRANCE: OVERVIEW OF THE SITUATION AFTER ONE YEAR OF IMPLEMENTATION AND FOCUS ON INNOVATIVE GENETICS PROCEDURES	Emilie Sam	French Ministry of Health, General Directorate for Healthcare Provision (DGOS/PF4)
PHP350	POLICIES FOR USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT: A COMPARATIVE STUDY OF 6 HTA AGENCIES	Amr Makady	The National Healthcare Institute (ZIN)
PHP351	WHAT IS REAL-WORLD DATA?: A REVIEW OF DEFINITIONS BASED ON LITERATURE & STAKEHOLDER INTERVIEWS	Amr Makady	The National Healthcare Institute (ZIN)
PHP387	PUBLIC CONSULTATION AS A TOOL FOR PATIENT AND PUBLIC INVOLVEMENT IN THE BRAZILIAN HTA PROCESS	Aline Silveira Silva	Brazilian Ministry of Health
PHP44	ARE WE INDEED FAST ADOPTERS AS WE CLAIM TO BE? AN ANALYSIS OF THE TIME INTERVAL FROM REGULATORY APPROVAL TO COVERAGE AND REIMBURSEMENT IN THE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL	D Greenberg	Ben-Gurion University of the Negev
PHP45	DO PHARMACEUTICAL COST CONTROL POLICIES EFFECTIVE IN REDUCING PHARMACEUTICAL EXPENDITURE AND VOLUME? A SYSTEMATIC REVIEW	Kah Seng Lee	Ministry of Health Malaysia
PHP53	DRUG PRICING AND REIMBURSEMENT PROCESSES IN ALGERIA	Redouane Soualmi	ISPOR Chapter Algeria

PHP61	COMPARING THE SAFETY PROFILES OF BIOSIMILARS WITH THEIR ORIGINATORS': A CROSS SECTIONAL ANALYSIS ON THE EU-RMP	Leroy Ricardo Adrianus Lepelaars	Utrecht University
PHP66	GENERIC DRUG UTILIZATION AMONG THE ELDERLY WITH MULTIPLE CHRONIC CONDITIONS IN THE UNITED STATES	Yifan Xu	University of Southern California
PHP72	UTILIZATION AND COST OF ANTIMICROBIALS USED IN MEDICINE AND SURGERY DEPARTMENTS OF A TERTIARY CARE TEACHING HOSPITAL	Bimba Haligeri Veerana Goud	Maulana Azad Medical College, University of Delhi
PHP74	INDUSTRIAL LANDSCAPE AND MARKET UPTAKE MODELS OF BIOSIMILARS AND OFF-PATENT BIOLOGICAL MEDICINES	Evelien Moorkens	KU Leuven
PHP77	RACIAL DISPARITIES IN ACCESS TO PHARMACY AND ITS SERVICES IN PENNSYLVANIA	Priti Pednekar	University of the Sciences
PHP96	COST OF LOST PRODUCTIVITY DUE TO PREMATURE, SUICIDE-RELATED MORTALITY IN POLAND	Katarzyna Orlewska	Medical University of Warsaw
PHP98	RELEVANCE AND ECONOMIC CONSEQUENCES OF MEDICINE WASTE IN VIENNA: ANALYSIS OF A HOUSEHOLD GARBAGE SAMPLE	Roger H.P.F. de Rooij	Utrecht University
PHP99	A SYSTEMATIC REVIEW: ECONOMIC BURDEN OF NEEDLESTICK INJURIES ON HEALTHCARE WORKERS	Hui Ling Huang	China Pharmaceutical University

**RESEARCH POSTER PRESENTATIONS - SESSION II: 15:45 - 19:45  
URINARY/KIDNEY DISORDERS**

PUK10	COST-EFFECTIVENESS ANALYSIS OF SUCROFERRIC OXYHYDROXIDE IN TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE	Dzhumber Ugrekhelidze	I.M. Sechenov First Moscow State Medical University
PUK19	THE EFFECT OF THERAPEUTIC DRUG MONITORING IN PATIENTS COMPLIANCE: AN IMPROVEMENT IN DRUG EFFICACY AND CORRESPONDING REDUCTION IN TOXICITY USING AMINOGLYCOSIDES	Kenneth Ikenna Okoro	UNIVERSITY OF NIGERIA, NSUKKA
PUK2	USE OF ANTIHYPERTENSIVE MEDICATIONS IN DIABETIC AND NON-DIABETIC CHRONIC KIDNEY DISEASE AND HEMODIALYSIS PATIENTS: A DUE STUDY	Prasanna Kumar	Manipal University
PUK6	BUDGET IMPACT ANALYSIS OF SUCROFERRIC OXYHYDROXIDE IN TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE	Dzhumber Ugrekhelidze	I.M. Sechenov First Moscow State Medical University

**RESEARCH POSTER PRESENTATIONS - SESSION III: 8:45 - 13:45  
MENTAL HEALTH**

PMH1	ANTIPSYCHOTIC DRUG PRESCRIBING, COST OF TREATMENT, ADVERSE DRUG REACTION MONITORING, AND QUALITY OF LIFE ASSESSMENT IN OUTPATIENTS OF A TERTIARY CARE HOSPITAL IN DELHI	Shankar Kumar	Maulana Azad Medical College, University of Delhi
------	---	---------------	---

PMH11	ADVANCED THERAPY MEDICINAL PRODUCTS FOR ALZHEIMER'S DISEASE WILL SHRINK THE NATIONAL HEALTH SERVICE BUDGET	Eve Hanna	Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université
PMH32	UTILITY VALUES IN ECONOMIC MODELS FOR TREATMENTS OF SCHIZOPHRENIA	Junwen Zhou	Creativ-Ceutical
PMH4	COST-EFFECTIVENESS OF INTERNET-DELIVERED COGNITIVE BEHAVIOR THERAPY FOR ADOLESCENT OBSESSIVE-COMPULSIVE DISORDER	Richard Ssegonja	Uppsala University
PMH42	THE PREVALENCE OF ATYPICAL ANTIPSYCHOTIC MEDICATION USE FOR PEDIATRIC PSYCHOSIS IN KOREA	Hankil Lee	College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University
PMH48	FEASIBILITY, RELIABILITY AND VALIDITY OF THE DECISION TOOL UNIPOLAR DEPRESSION (DTUD) IN IDENTIFYING PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN NEED OF HIGHLY SPECIALIZED CARE	Frédérique Cornélie Wilhelmina van Krugten	Erasmus University Rotterdam
PMH49	EARLY INDICATORS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN NEED OF HIGHLY SPECIALIZED CARE: A SYSTEMATIC REVIEW	Frédérique Cornélie Wilhelmina van Krugten	Erasmus University Rotterdam

**RESEARCH POSTER PRESENTATIONS - SESSION III: 8:45 - 13:45  
MUSCULAR-SKELETAL DISORDERS**

PMS30	MARKET REGULATION MAY INFLUENCE DRUG PRICE TRAJECTORIES - A COMPARISON OF ANTI TUMOR NECROSIS FACTOR DRUG PRICES IN ISRAEL AND THE USA	Noa Gordon	Ben-Gurion University of the Negev
PMS33	THE COSTS OF RHEUMATOID ARTHRITIS IN FINLAND	Jaana T Joensuu	University of Helsinki
PMS40	COST ANALYSIS OF INTRATHECAL BACLOFEN THERAPY FOR THE TREATMENT OF SPASTIC CEREBRAL PALSY IN THE RUSSIAN FEDERATION	Dzhumber Ugrehelidze	I.M. Sechenov First Moscow State Medical University
PMS43	A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS	Saara Huoponen	University of Helsinki
PMS5	TREATMENT OF OSTEOCHONDRAL FRACTURE AND MEDIAL PATELLOFEMORAL LIGAMENT RUPTURE AFTER PATELLAR DISLOCATION	Jussi Petteri Repo	Central Hospital of Central Finland, Jyväskylä, Finland
PMS52	COST-UTILITY OF UNICOMPARTMENTAL COMPARED TO TOTAL KNEE REPLACEMENTS: AN ANALYSIS BASED ON MATCHED ROUTINELY-COLLECTED DATA FROM THE UNITED KINGDOM	Edward Burn	Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
PMS58	A COST-EFFECTIVENESS ANALYSIS OF BIOSIMILAR INFliximab (INFLECTRA®) FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN NINE EUROPEAN COUNTRIES	Fanni Rencz	Corvinus University of Budapest
PMS6	THE THERAPEUTIC INDICATION OF INJECTABLE BEVACIZUMAB TO THE TREATMENT OF AGE-RELATED MUSCULAR DEGENERATION	Maria Danielly Lima Oliveira	Universidade Federal de Pernambuco

PMS60	COST-UTILITY ANALYSIS OF INJECTING A "DEXAMETHASONE ROPIVACAINE" MIXTURE SUBCUTANEOUSLY IN THE MANAGEMENT OF TRAUMATIC BONE SURGERIES OF THE FOREFOOT	Benoit Dalifard	La Rochelle Hospital
PMS7	ASSESSMENT OF CTX-1 BONE BIOMARKER AS AN INDICATOR OF ANTIRESORPTIVE THERAPY EFFICACY AND OF PERSISTENCE IN A FRACTURE LIAISON SERVICE	Andrea Senay	Université de Montréal
PMS75	RELIABILITY AND VALIDITY STUDY OF THE FINNISH ADAPTATION OF SCOLIOSIS RESEARCH SOCIETY QUESTIONNAIRE VERSION SRS-30	Jussi Petteri Repo	Central Hospital of Central Finland, Jyväskylä, Finland
PMS77	COMORBIDITIES AND PATIENT-REPORTED OUTCOME AFTER TOTAL HIP ARTHROPLASTY	Fanny L. Loth	Medical University of Innsbruck

**RESEARCH POSTER PRESENTATIONS - SESSION III: 8:45 - 13:45  
RESPIRATORY-RELATED DISORDERS**

PRS2	EXAMINING THE ASSOCIATION BETWEEN CORTICOSTEROID EXPOSURE AND NEW ONSET TYPE 2 DIABETES AMONG COMMERCIALY INSURED COPD PATIENTS IN THE US	Cynthiya Ruban	University of North Carolina Charlotte
PRS24	HOW MUCH DOES AN ASTHMA-RELATED EVENT COST IN A MALAYSIAN SUBURBAN HOSPITAL?	Yee Vern Yong	Universiti Sains Malaysia
PRS25	HEALTH CARE COSTS AMONG COPD PATIENTS ARE DOUBLED COMPARED TO A CONTROL POPULATION	Emin Hoxha Ekström	Sahlgrenska Academy, University of Gothenburg
PRS42	COST-EFFECTIVENESS ANALYSES OF PHARMACOLOGIC MAINTENANCE TREATMENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A SYSTEMATIC REVIEW	Simon van der Schans	University of Groningen
PRS49	SYSTEMATIC REVIEW OF HEALTH STATE UTILITIES IN CHILDREN WITH ASTHMA	Wei Sun Kua	University of Sheffield
PRS55	VALIDITY OF THE EQ-5D-YOUTH IN ASTHMATIC CHILDREN	Karina Mayoral	Hospital del Mar Research Institute
PRS65	TRENDS IN UTILIZATION OF SMOKING CESSATION AGENTS BEFORE AND AFTER THE PASSAGE OF BLACK BOX WARNING IN THE UNITED STATES	Drishti R Shah	West Virginia University, School of Pharmacy
PRS66	TRENDS IN THE UTILIZATION, SPENDING, AND PRICES FOR SMOKING CESSATION AND NICOTINE REPLACEMENT PRODUCTS IN US MEDICAID PROGRAMS: 1991-2015	Xiaomeng Yue	University of Cincinnati College of Pharmacy
PRS67	STUDY ON AGE-RELATED DRUG USE PATTERN AND ASSESSMENT OF MEDICATION ADHERENCE IN PATIENTS WITH CHRONIC RESPIRATORY DISEASES	Bidhata Khatri	Acharya and BM Reddy College of Pharmacy

**RESEARCH POSTER PRESENTATIONS - SESSION III: 8:45 - 13:45  
SENSORY SYSTEMS DISORDERS**

PSS14	ASSESSMENT OF ADHESION RESPONSE TO 3D PRINTED MATERIALS FOR OPHTHALMIC DEVICE DEVELOPMENT	Maryam Alband	UCL School of Pharmacy
-------	---	---------------	------------------------

PSS38	COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO DEXAMETHASONE IN PATIENTS WITH RETINAL VEIN OCCLUSION (RVO) FROM A PORTUGUESE HEALTH CARE PERSPECTIVE	Bárbara Montóia	Novartis Farma – Produtos Farmaceuticos S.A.
PSS51	CONSTRUCT VALIDITY OF THE 10-YEAR TIME TRADE-OFF METHOD IN PSORIASIS PATIENTS	Fanni Rencz	Corvinus University of Budapest
PSS60	MEASUREMENT PROPERTIES OF THE EQ-5D-5L COMPARED TO THE EQ-5D-3L IN PSORIASIS PATIENTS	Fanni Rencz	Corvinus University of Budapest

**RESEARCH POSTER PRESENTATIONS - SESSION III: 8:45 - 13:45  
SYSTEMIC DISORDERS/CONDITIONS**

PSY116	LINGUISTIC VALIDATION OF THE FINNISH VERSION OF THE BODY-Q PRO INSTRUMENT	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PSY122	ORPHAN DRUG SHORTAGE IN THE UNITED STATES: A LONG LASTING PUBLIC HEALTH ISSUE CALLING FOR EFFECTIVE POLICIES	Chiraz Azaiez	Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université
PSY123	WAR RAGES BETWEEN INFLIXIMAB BIOSIMILARS AND THEIR ORIGINATOR	Anais Loubiere	General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP)
PSY124	ASSOCIATION BETWEEN ORPHAN DRUG PRICES AND THERAPEUTIC AREA	Daria Korchagina	University of Paris-Sud
PSY125	DETERMINANTS OF ORPHAN DRUG PRICES IN ITALY AND THE UK	Daria Korchagina	University of Paris-Sud
PSY126	ASSOCIATION BETWEEN DISEASE PREVALENCE, DRUG PRICE AND ASMR FOR ORPHAN DRUGS IN FRANCE	Daria Korchagina	University of Paris-Sud
PSY130	CHOICE OF FIRST OPIOID PRESCRIPTION AND THE TRANSITIONS FROM ACUTE TO LONG TERM OPIOID USE – FINDINGS FROM BIG DATA	Anuj B Shah	University of Arkansas for Medical Sciences
PSY138	WHAT DRIVES ASMR OF ORPHAN DRUGS?	Daria Korchagina	University of Paris-Sud
PSY140	COST-EFFECTIVENESS OF PROPHYLAXIS COMPARED TO ON-DEMAND TREATMENT IN SEVERE HAEMOPHILIA A. SYSTEMATIC REVIEW	Irina Odnoletkova	Plasma Protein Therapeutics Association
PSY146	ELEMENTS OF ORPHAN DRUGS VALUE	Daria Korchagina	University of Paris-Sud
PSY155	REVIEW OF NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS ON TREATMENT OF SEVERE HAEMOPHILIA A	Irina Odnoletkova	Plasma Protein Therapeutics Association
PSY19	TREATMENT COMPARATIVE EFFECTIVENESS IN RARE DISEASES: THE CASE OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY SURVIVAL	Mónica Inês	Instituto de Medicina Molecular
PSY29	TEMPORAL TRENDS IN TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY NATURAL SURVIVAL OVER A CENTURY	Mónica Inês	Instituto de Medicina Molecular
PSY32	MEDICAL COSTS ATTRIBUTABLE TO OBESITY IN WORKING OSTEO-ARTHRITIS PATIENTS IN THE US	Yong Chan CHOI	Chung-Ang University
PSY4	HYPERTENSION IS ASSOCIATED WITH WORSE OUTCOMES AMONG HOSPITALIZED CHILDREN WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN THE US	Laura A. Clark	University of North Carolina at Charlotte

PSY44	COSTS OF MULTIPLE MYELOMA MANAGEMENT AND TREATMENT FOR ELDERLY PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES IN THE SERBIAN HEALTH CARE SYSTEM	Ursula Rochau	UMIT - University for Health Sciences, Medical Informatics and Technology, Department of Public Health, Health Services Research and Health Technology Assessment/ONCOTYROL - Center for Personalized Cancer Medicine, Area Health Technology Assessment
PSY5	KIDNEY-RELATED COMPLICATIONS ARE ASSOCIATED WITH WORSE OUTCOMES AMONG HOSPITALIZED CHILDREN WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN THE US	Laura A. Clark	University of North Carolina at Charlotte
PSY50	ECONOMIC CONSIDERATIONS ON THE USE OF RECOMBINANT VS. PLASMATIC FACTOR VIII IN THE TREATMENT OF PREVIOUSLY UNTREATED HAEMOPHILIA A PATIENTS	Basma Wali	Hochschule Fresenius
PSY78	COST-EFFECTIVENESS OF ACUPUNCTURE VERSUS STANDARD CARE FOR PELVIC AND LOW BACK PAIN IN PREGNANCY: AN ANALYSIS OF THE GAME RANDOMIZED TRIAL	Thibault Butel	APHP
PSY82	DEVELOPMENT OF AN ECONOMIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF NITISINONE AS A TREATMENT FOR ALKAPTONURIA IN THE UK	Ciaran McCarron	City University, London
PSY90	COST-UTILITY ANALYSIS OF LORCASERIN IN THE TREATMENT OF OBESITY	Zahra Sharif	Shahid Beheshti University of Medical Sciences, School of Pharmacy
PSY92	AN UPDATE OF REAL-WORLD COST-UTILITY EVALUATION OF MULTIPLE MYELOMA TREATMENTS IN STEM CELLS TRANSPLANT PATIENTS	Federico Parada-Saavedra	Hospital Universitari Arnau de Vilanova

**RESEARCH POSTER PRESENTATIONS - SESSION IV: 15:15 - 19:15**  
**CARDIOVASCULAR DISORDERS**

PCV100	COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN IRANIAN ATRIAL FIBRILLATION PATIENTS	Ehsan Sanati	Tehran University of Medical Sciences
PCV112	WILL STEM CELLS FOR HEART FAILURE BE THE NEXT SOFOSBUVIR ISSUE?	Eve Hanna	Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université
PCV115	ASSESSMENT OF MEDICATION ADHERENCE AND THE ASSOCIATED COST OF CALENDAR BLISTER PACK AMONG HYPERTENSIVE PATIENTS IN MALAYSIA	Bee Ying Tan	Universiti Sains Malaysia
PCV116	PATIENTS' RATINGS OF MEDICATION TELL THE NEED FOR TAILORED MEDICATION COUNSELING: A MULTILEVEL ANALYSIS	Hyeonjin Kang	Seoul National University
PCV120	UTILITY MEASURES AND QUALITY-ADJUSTED LIFE YEARS IN PATIENTS WITH SYMPTOMATIC MULTIVESSEL CORONARY ARTERY DISEASE ASSIGNED TO SURGERY, ANGIOPLASTY OR MEDICAL TREATMENT – MASS II TRIAL	Sara Michelly Goncalves Brandao	Heart Institute (InCor) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

PCV121	CAREGIVER BURDEN AND QUALITY OF LIFE OF INFORMAL CAREGIVERS OF STROKE PATIENTS: A PROSPECTIVE STUDY	Enkhzaya Chuluunbaatar	Mongolian Stroke Association
PCV124	WILLINGNESS TO PAY FOR A QUALITY-ADJUSTED LIFE YEAR OF OUTPATIENTS WITH CARDIOVASCULAR DISEASES	Thi Thanh Thao Nguyen	University of medicine and pharmacy, Ho Chi Minh City
PCV126	FINANCIAL ANALYSIS OF THE FINAL PRICES, CO-PAYMENTS AND REIMBURSEMENT OF ANTIHYPERTENSIVES IN SLOVAKIA FROM 2008-2014	Zuzana Haramiova	Comenius University, Faculty of Pharmacy
PCV132	UTILISATION OF ANTITHROMBOTIC DRUGS IN SLOVAKIA	Zuzana Haramiova	Comenius University, Faculty of Pharmacy
PCV136	CARDIOVASCULAR DRUG UTILISATION IN SLOVAKIA, MAIN REGIONAL CHARACTERISTICS	Zuzana Haramiova	Comenius University, Faculty of Pharmacy
PCV137	ANALYSIS OF AFFORDABILITY AND CONSUMPTION OF ANTIHYPERTENSIVE FIXED COMBINATIONS OF DRUGS IN UKRAINE	Mariia Mishchenko	National University of Pharmacy
PCV14	NON-VALVULAR ATRIAL FIBRILLATION: CAN WE IMPROVE HEALTH OUTCOMES?	Mónica Inês	Laboratórios Pfizer Lda.
PCV15	ADHERENCE TO RIVAROXABAN, DABIGATRAN, AND APIXABAN FOR STROKE PREVENTION IN INCIDENT, TREATMENT-NAIVE NON-VALVULAR ATRIAL FIBRILLATION <b>** WITHDRAWN **</b>	Joshua Brown	University of Kentucky
PCV17	EFFECTIVENESS AND INEQUALITY ESTIMATION OF ANTIHYPERTENSIVE MEDICINES' UTILIZATION IN IRAN ACCORDING TO OBSERVATIONAL DATA: 2002-2011	Amir Hashemi-Meshkini	Tehran University of Medical Sciences
PCV21	COMPARATIVE EFFECTIVENESS OF BRAND-NAME AND GENERIC WARFARIN ON STROKE AND BLEEDING EVENTS IN ATRIAL FIBRILLATION PATIENTS: A 6-YEAR POPULATION-BASED RETROSPECTIVE COHORT STUDY IN TAIWAN	Dan Wei Choo	National Taiwan University
PCV22	THE IMPACT OF UNDERUSING LIPID-LOWERING MEDICATIONS ON THE RISK OF HEART ATTACK AND HOSPITALIZATIONS IN UNITED STATES ELDERLY POPULATION	Wei-Han Cheng	University of Southern California
PCV24	EFFECTIVENESS AND SAFETY OF THROMBOLYTIC AGENTS STREPTOKINASE, ALTEPLASE AND TENECTEPLASE IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION	Bruna Oliveira Ascef	Public Health, College of Medicine, Federal University of Minas Gerais
PCV25	PROTON PUMP INHIBITORS AND MAJOR ADVERSE CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW	Nawal Farhat	University of Ottawa
PCV31	FACTORS ASSOCIATED WITH THE USE OF COMPLEMENTARY MEDICINES IN HYPERTENSION	Inas Ibrahim	Universiti Sains Malaysia
PCV34	THE EFFECT OF RAS-MODIFYING MEDICATIONS ON PULMONARY COMPLICATIONS IN PATIENTS WITH HYPERTENSION	Soo In Bang	University of Southern California
PCV42	THE POTENTIAL BUDGET IMPACT OF PCSK9 INHIBITORS IN IRELAND	Helen O'Donnell	National Centre for Pharmacoeconomics

PCV5	EVALUATION OF SULPHONYLUREA INDUCED CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COMPARISON WITH NON SULPHONYLUREA AT SOUTH INDIAN TEACHING HOSPITAL	Radhakrishnan Rajesh	Manipal College of pharmaceutical sciences, Manipal University, MANIPAL, INDIA
PCV50	COST-ANALYSIS OF HEART VALVE IMPLANTATIONS, COMPLICATIONS AND FOLLOW-UP BASED ON NATIONAL HEALTH INSURERS CLAIMS DATA IN THE NETHERLANDS	Simone A. Huygens	Erasmus Medical Centre
PCV51	SYSTEMATIC REVIEW OF COST EFFECTIVENESS ANALYSIS OF IVABRADINE IN HEART FAILURE	Mina Dehghani	Tehran University of Medical Sciences
PCV53	ASSESSING THE ECONOMIC BURDEN OF HEART FAILURE IN KOREA: INCREMENTAL COST APPROACH	Sung-Hee Oh	College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University
PCV74	INPATIENT TREATMENT COST OF STROKE: AN ANALYSIS IN HO CHI MINH CITY 115 PEOPLE'S HOSPITAL, VIETNAM	Thi Ngoc Thanh Le	University of Medicine and Pharmacy, Ho Chi Minh City
PCV75	INPATIENT TREATMENT COST OF POST-STROKE: AN ANALYSIS IN HOSPITAL OF OCCUPATIONAL DISEASES AND REHABILITATION, VIETNAM	Thi Ngoc Thanh Le	University of Medicine and Pharmacy, Ho Chi Minh City
PCV76	COST OF TREATMENT HYPERTENTION INPATIENTS IN VIETNAM	Thi Thu Thuy Nguyen	University of medicine and pharmacy, Ho Chi Minh City
PCV79	TREATMENT COST OF POST MYOCARDIAL INFARCTION: AN ANALYSIS IN HEART INSTITUTE IN HO CHI MINH CITY, VIETNAM	Thi Thanh Thao Nguyen	University of medicine and pharmacy, Ho Chi Minh City
PCV92	COST-EFFECTIVENESS ANALYSIS OF SERELAXIN IN TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE	George Tolordava	I.M. Sechenov First Moscow State Medical University
PCV93	COST-EFFECTIVENESS ANALYSIS OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTINGâ€“MASS III 5-YEAR FOLLOW-UP	Thiago L Scudeler	Heart Institute (InCor) University of Sao Paulo
PCV95	BUDGET IMPACT ANALYSIS OF STANDARD CARE WITH SERELAXIN IN TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE	George Tolordava	I.M. Sechenov First Moscow State Medical University
PCV96	A COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN AGAINST ATORVASTATIN IN CARDIOVASCULAR DISEASES AND STROKE: AN AMBISPECTIVE STUDY	Bireddy Deepthy	St.Peter's institute of pharmaceutical sciences

**RESEARCH POSTER PRESENTATIONS - SESSION IV: 15:15 - 19:15  
DIABETES/ENDOCRINE DISORDERS**

PDB106	A COMPARISON OF INSULIN DEGLUDEC CLINICAL EVALUATIONS AND RECOMMENDATIONS BETWEEN AN INDEPENDENT HTA AND NATIONAL HTA BODIES	Elisabeth M. Oehrlein	University of Maryland, School of Pharmacy
PDB11	NETWORK META-ANALYSIS OF ANTIDIABETIC TREATMENTS ADDED TO INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	Jeong-Hwa Yoon	Seoul National University College of Medicine



PDB37	COST OF TREATMENT OF PANCREAS TRANSPLANTATION THERAPY AND INSULIN PUMP THERAPY OF TYPE I DIABETES MELLITUS	Ondřej Gajdoš	Czech Technical University in Prague
PDB64	ADHERENCE TO ORAL ANTIDIABETIC MEDICATION IN TYPE 2 DIABETES MELLITUS CLIENTS IN THE VOLTA REGION OF GHANA	Israel Abebrese Sefah	GHANA HEALTH SERVICE
PDB91	IMPROVING THE SYSTEM OF HEALTHCARE PROVISION FOR PATIENTS WITH DIFFUSE TOXIC GOITER IN UKRAINE	Yuliia Vadziuk	Ivan Horbachevsky Ternopil State Medical University
PDB96	DISPENSING PATTERNS AND COST OF INSULINS IN POLAND BETWEEN 2012 AND 2015	Katarzyna Orlewska	Medical University of Warsaw

**RESEARCH POSTER PRESENTATIONS - SESSION IV: 15:15 - 19:15  
HEALTH SERVICES**

PHS102	EVALUATING EFFECTIVENESS AND PERSISTENCY OF A PHARMACIST-LED DISEASE MANAGEMENT PROGRAM	Zifan Zhou	University of Southern California
PHS105	IMPACT OF STATE MANDATED QUERIES OF THE PRESCRIPTION DRUG MONITORING PROGRAMS ON OPIOID AND NON-OPIOID DRUG RELATED ADVERSE EFFECTS: A DIFFERENCE IN DIFFERENCE APPROACH	Corey J. Hayes	University of Arkansas for Medical Sciences College of Pharmacy
PHS111	EVALUATING FACTORS ASSOCIATED WITH DEPRESSIVE SYMPTOMS AMONG POSTPARTUM MOTHERS IN SOUTH PUNJAB, PAKISTAN	Ahmad Zia	The Islamia University of Bahawalpur
PHS114	KNOWLEDGE OF BLOOD PRESSURE CONTROL PROGRAMS IN UNIVERSITY STUDENTS	Erika Paola Viana Cardenas	Universidad del Norte
PHS118	COST OF HEALTHCARE AMONG METASTATIC LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY	Bradley C. Martin	University of Arkansas for Medical Sciences College of Pharmacy
PHS12	CAESAREAN SECTION IN XINDU COUNTY OF CHENGDU, CHINA: TREND AND ITS CORRELATES FROM 2008 TO 2014	Ping Zhu	Sichuan University
PHS126	COST-EFFECTIVENESS ANALYSIS OF AN AUTOMATED MEDICATION SYSTEM IMPLEMENTED IN A DANISH HOSPITAL SETTING	Bettina Wulff Risør	University of Southern Denmark
PHS138	ECONOMIC BENEFITS OF THE BABY FRIENDLY HOSPITAL INITIATIVE IN A SECOND CARE HOSPITAL IN MÉXICO	Héctor May	Quintana Roo University
PHS149	RISK OF MOTOR-VEHICLE ACCIDENTS INCREASES WITH MULTIMORBIDITY	Yannick Fortin	University of Ottawa
PHS150	THE IMPACT OF PHARMACIST INTERVENTION ON MEDICATION ERRORS IN A TEACHING HOSPITAL QUETTA, PAKISTAN	Noman Haq	University of Balochistan
PHS151	VALUE OF THE CLINICAL DECISION SUPPORT SYSTEM FOR ADVERSE DRUG EVENT PREVENTION: A COST-EFFECTIVENESS ANALYSIS AND COST-BENEFIT ANALYSIS	Sukhyang Lee	Ajou University

PHS155	ASSESSMENT OF KNOWLEDGE OF URINARY TRACT INFECTION (UTI) AMONGST SCHOOL-GOING ADOLESCENT GIRLS	Ruchi Bokolia	K. B. Institute of Pharmaceutical Education & Research
PHS157	A QUALITATIVE STUDY EXPLORING PERCEPTION AND ATTITUDES OF COMMUNITY PHARMACISTS ABOUT EXTENDED PHARMACY SERVICES IN LAHORE, PAKISTAN	Furqan Khurshid Hashmi	Universiti Sains Malaysia
PHS158	METHODOLOGY OF RESEARCH TO DETERMINE COST AND UTILITY OF PILOT ONE-STOP FERTILITY CLINIC VERSUS TRADITIONAL NHS FERTILITY INVESTIGATION PATHWAY	Moses Batwala	Oxford University
PHS16	MEASURING THE RELATIONSHIP BETWEEN HOSPITAL COSTS AND QUALITY OF CARE: AN EXAMPLE OF ACUTE MYOCARDIAL INFRACTION IN EDMONTON, ALBERTA, CANADA	Filmer Chu	University of Alberta
PHS162	A QUALITATIVE STUDY EVALUATING THE ATTITUDE AND PERCEPTION OF PHYSICIAN AND PHARMACIST TOWARDS PHARMACOVIGILANCE IN ABBOTTABAD, PAKISTAN	Akash Syed	Department of Pharmacy, COMSATS Institute of Information Technology
PHS163	ASSESSMENT OF KNOWLEDGE, ATTITUDE AND BARRIERS TOWARDS ADRS REPORTING AMONG HEALTHCARE PROFESSIONALS OF ABBOTTABAD, PAKISTAN	Akash Syed	Department of Pharmacy, COMSATS Institute of Information Technology
PHS166	ECONOMIC BURDEN OF STROKE: A SYSTEMATIC REVIEW ON POST-STROKE CARE	Sasa Rajsic	UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment
PHS167	HEALTH-RELATED QUALITY OF LIFE OF USERS OF PRIMARY CARE IN BRAZIL	Bruna Oliveira Ascef	Public Health, College of Medicine, Federal University of Minas Gerais
PHS171	HEALTH-RELATED QUALITY OF LIFE OF PATIENTS IN PRIMARY CARE AND MULTIMORBIDITY	Aurea Jordán-Alfonso	Universitat Politècnica de València
PHS172	THE TRENDS OF EMERGENCY CARE ADMISSIONS FOCUSING ON THE POPULATION OVER 65 YEARS OF AGE	Fanni Farkas Borbás	Eötvös Loránd University
PHS175	COST-EFFECTIVENESS ANALYSIS OF COLORECTAL CANCER SCREENING IN AUSTRIA AND ASSESSMENT OF THE IMPACT OF CANCER-CAUSING RISK FACTORS	Mariella Gloria Gregorich	University of Technology Vienna
PHS178	WHAT IS THE LEVEL OF TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT PROCESS IN HUNGARY, ROMANIA AND TURKEY?	Mihaela-Simona Subtirelu	University of Medicine and Pharmacy
PHS182	BARRIERS INFLUENCING IMPLEMENTATION OF GUIDELINES INTO CLINICAL PRACTICE IN CZECH REPUBLIC	Jana Bartakova	1st Faculty of Medicine Charles University in Prague
PHS22	COMPARING COSTS FROM A PRAGMATIC RANDOMISED TRIAL TO PUBLISHED MODELLING-BASED ESTIMATES: AN EXAMPLE FROM PROSTATE-CANCER SCREENING	Neill Booth	University of Tampere

PHS26	THE PRESCRIBING, INPATIENT, OUTPATIENT AND SOCIAL CARE COSTS ASSOCIATED WITH ATRIAL FIBRILLATION IN SCOTLAND: A RECORD LINKAGE STUDY	Giorgio Ciminata	University of Glasgow
PHS46	CLINICAL AND ECONOMIC BENEFITS OF A COMMUNITY PHARMACY VACCINATION STRATEGY	James Gallagher	University College Cork
PHS50	COST-EFFECTIVENESS ANALYSIS OF COMPREHENSIVE MEDICATION REVIEW (CMR) FOR PATIENTS ACUTELY ADMITTED TO HOSPITAL	Tomasz Szymanski	Imperial College London
PHS51	COST-EFFECTIVENESS OF THE PHARMACIST-ASSISTED WARFARIN MONITORING PROGRAM (PAWM) AT A MEDICAL CENTER IN TAIWAN	Jen-Yu Chang	National Taiwan University
PHS54	COST-UTILITY ANALYSIS OF BURNS MANAGEMENT IN NIGERIA: A CASE STUDY OF NATIONAL ORTHOPAEDIC HOSPITAL, ENUGU	Charles Ebuka Okafor	Nnamdi Azikiwe University, Awka
PHS55	HEALTHCARE REFORM PLAN AND PRICE ELASTICITY IN VAGINAL DELIVERY: A CASE STUDY IN IRAN	Ali Akbari-Sari	Tehran University of Medical Sciences
PHS59	HEALTH CARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH THE MANAGEMENT OF NON-INFECTIOUS INTERMEDIATE, POSTERIOR AND PANUVEITIS IN CANADA	Véronique Lambert-Obry	University of Montreal
PHS6	EFFECTIVENESS AND COST-EFFECTIVENESS OF THE SALUT PROGRAMME – A UNIVERSAL HEALTH PROMOTION INTERVENTION FOR PARENTS AND CHILDREN	Filipa Sampaio	Uppsala University
PHS65	IMPACT OF COMORBIDITIES ON MEDICATION ADHERENCE IN HYPERTENSIVE PATIENTS	Pranitha Arukala	St.Peter's Institute of Pharmaceutical Sciences
PHS67	ANALYSIS OF THE FACTORS AFFECTING PARENTS' MEDICATION ADHERENCE IN ASTHMATIC CHILDREN USING EXPECTATION CONFIRMATION THEORY	Yasser Almogbel	University of Houston
PHS68	ONE-YEAR PATIENT-REPORTED PERSISTENCE TO ANTIRESORPTIVE TREATMENT IN A FRACTURE LIAISON SERVICE: THE LUCKY BONE™ PROGRAM	Andrea Senay	Université de Montréal
PHS70	IMPACT OF ANIMAL TESTING ON MENTAL HEALTH OF RESEARCHERS	Minji Kang	Ewha Womans University
PHS71	A REAL-WORLD OUTCOME RESEARCH STUDY ON QUALITY OF LIFE, WORK PRODUCTIVITY AND HEALTHCARE RESOURCE UTILIZATION IN METASTATIC BREAST CANCER FOR PATIENTS AND CAREGIVERS	Véronique Lambert-Obry	University of Montreal
PHS72	EVALUATING THE EXPERIENTIAL QUALITY OF OLDER PEOPLE'S COMMUNITY CARE: A CONCEPT MAPPING APPROACH TO INSTRUMENT DESIGN	Mark Wilberforce	University of Manchester
PHS93	DRG APPROPRIATENESS ANALYSIS USING ACTIVITY-BASED-COSTING METHOD – A CASE OF BURN DIAGNOSIS	Silvie Jerabkova	Czech Technical University in Prague

PHS98	ECONOMIC CONSEQUENCES OF THE DETERMINALISTIC RELATION BETWEEN LABORATORY TESTS INDICATION AND ANTIBIOTIC PRESCRIPTION	Zuzana Haramiova	Comenius University, Faculty of Pharmacy
-------	---	------------------	--

**RESEARCH POSTER PRESENTATIONS - SESSION V: 8:45 - 13:45  
CANCER**

PCN104	ECONOMIC EVALUATION OF TARGETED THERAPIES IN METASTATIC CLEAR RENAL CELL CARCINOMA IN CANADA	Sara Nazha	McGill University Health Centre
PCN110	DRUG UTILISATION OF BRAF INHIBITORS FOR MELANOMA IN IRELAND	Claire Gorry	National Centre for Pharmacoeconomics
PCN14	COMPARATIVE EFFECTIVENESS OF TREATMENT STRATEGIES FOR MULTIPLE MYELOMA IN ELDERLY PATIENTS: A NETWORK META-ANALYSIS	Monika Buchberger	UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment
PCN142	COST-EFFECTIVENESS ANALYSIS OF ORAL FENTANYL FORMULATIONS FOR BREAKTHROUGH CANCER PAIN TREATMENT	Lucia Sara D'Angiolella	University of Milan Bicocca
PCN147	IS THE INTEGRATED ELECTRONIC HEALTH RECORD COST-EFFECTIVE FOR A CANCER CONSULTATION? RESULTS FROM THE E-SI (PREPS-SIPS) STUDY	L Perrier	Cancer Centre Léon Bérard
PCN154	COST-EFFECTIVENESS ANALYSIS OF LIPEGFILGRASTIM IN PROPHYLAXIS OF FEBRILE NEUTROPENIA IN CANCER PATIENTS	Dzhumber Ugrehelidze	I.M. Sechenov First Moscow State Medical University
PCN163	PERSONALIZED MAMMOGRAPHY SCREENING AND RISK-ADJUSTED SCREENING ADHERENCE - ANALYSIS OF COST-EFFECTIVENESS	Matthias Arnold	LMU Munich
PCN180	COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS	Marscha Shih-Ching Holleman	Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam
PCN186	HEALTHCARE RESOURCE USE ALONGSIDE NOVEL TREATMENTS FOR ADVANCED MELANOMA IN THE NETHERLANDS	B. Leeneman	Erasmus University Rotterdam
PCN191	HEALTHCARE RESOURCE UTILISATION IS ASSOCIATED WITH PHASE OF CHRONIC MYELOID LEUKAEMIA (CML): RESULTS OF A CLINICAL EXPERT SURVEY IN ENGLAND AND WALES	Rachel E Robson	Tolley Health Economics
PCN204	IMPACTS OF ADVERSE EVENTS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS RECEIVING FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER: RESULTS FROM RANDOMIZED PHASE III SELECT BC STUDY	Yasuhiro Hagiwara	The University of Tokyo

PCN205	COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AND ITS ASSOCIATION WITH QUALITY OF LIFE AMONG CANCER PATIENTS RECEIVING CHEMOTHERAPY IN ETHIOPIA: A CROSS SECTIONAL STUDY	Daniel Asfaw Erku	University of Gondar
PCN211	ASSESSMENT OF KNOWLEDGE AND PERCEPTION REGARDING BREAST CANCER AMONG PATIENTS ATTENDING GYNECOLOGICAL DEPARTMENT OF TERTIARY CARE HOSPITAL IN QUETTA PAKISTAN	Noman Haq	University of Balochistan
PCN212	TREATMENT OF UPPER-EXTREMITY SARCOMA WITH LIMB-SALVAGE PROCEDURES SHOWED GOOD FUNCTIONAL OUTCOMES: A PILOT STUDY OF 13 CONSECUTIVE PATIENTS	Jussi Petteri Repo	University of Helsinki and Helsinki University Hospital
PCN229	MISSED OPPORTUNITIES IN THE NETHERLANDS: THE NEGLIGENCE OF NON-STATISTICAL UNCERTAINTY IN CED POLICY	Xavier G. L. V. Pouwels	Maastricht University Medical Center+
PCN261	BURDEN OF EARLY AND ADVANCED BREAST CANCER IN THE NETHERLANDS	Gerard T Vondeling	University of Groningen
PCN27	THE THERAPEUTIC INDICATION OF CAPSULE AND INJECTABLE ETOPOSIDE TO THE TREATMENT OF OSTEOSARCOMA	Tiago Rafael Sousa Nunes	UFPE
PCN276	CONTINENTAL COMPARISON OF INNOVATIVE DRUGS PRICES, THE CASE OF ONCOLOGY USED FOR TREATMENT OF SOLID TUMORS IN GERMANY AND THE UNITED STATES	Najah Aissaoui	Paris Dauphine University
PCN280	MARKET ACCESS OF INNOVATIVE ANTICANCER DRUGS IN ALGERIA: FUNDING BASED ON CLINICAL OR ECONOMIC EVIDENCE?	Amine Aissaoui	Paris Dauphine University, PSL
PCN282	GEOGRAPHIC, RACIAL, AND TEMPORAL VARIATIONS OF ADHERENCE TO SCREENING FOR CERVICAL CANCER AND HPV VACCINATION IN THE UNITED STATES, 2008-2012	Xue Feng	West Virginia University, School of Pharmacy
PCN283	IS EXTERNAL REFERENCE PRICING A THREAT TO INTERNATIONAL EQUAL AFFORDABILITY?	Amir Ansaripour	Erasmus University Rotterdam
PCN315	PHYSICIANS' BEHAVIOR INFLUENCES THE HEALTH AND ECONOMIC IMPACT OF APPLYING CIRCULATING TUMOR CELLS AS RESPONSE MARKER IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	Koen Degeling	University of Twente
PCN33	GEFITINIB, ERLOTINIB OR AFATINIB FOR EGFR MUTATED NSCLC PATIENTS? A META-ANALYSIS AND INDIRECT COMPARISON ON THE EFFICACY OF FIRST-LINE TYROSINE KINASE INHIBITORS	Marscha Shih-Ching Holleman	Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam
PCN47	REAL LIFE PROGRESSION FREE SURVIVAL AND TREATMENT PATTERNS FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPIES IN FRANCE: ANALYSIS OF IMS RWD ONCOLOGY CROSS-SECTIONAL SURVEY DATA	Rana Maroun	GSK France

PCN48	PIVOTAL STUDIES OF ONCOLOGY DRUGS APPROVED IN EUROPE, WHICH EVIDENCE BASED-MEDICINE?	Amine Aissaoui	Paris Dauphine University, PSL
PCN5	REAL-WORLD OUTCOMES OF IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN THE NETHERLANDS	B. Leeneman	Erasmus University Rotterdam
PCN52	OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS	Amine Aissaoui	Paris Dauphine University, PSL
PCN54	CHOOSING FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER BASED ON BIOMARKER RAS STATUS: A BUDGET IMPACT ANALYSIS FROM BRAZILIAN HEALTH INSURANCE SYSTEM PERSPECTIVE	Paulo V S Souza	Merck
PCN74	WHAT IS AN EFFICIENT AND AFFORDABLE TRASTUZUMAB THERAPY IN A MIDDLE-INCOME COUNTRY? - ADJUVANT THERAPY WITH TRASTUZUMAB IN MANAGEMENT OF EARLY HER2-POSITIVE BREAST CANCER IN IRAN	Amir Ansari pour	Erasmus University Rotterdam
PCN76	THE INFLUENCE OF PRICE REGULATION METHOD ON PRICE TRAJECTORY – ASSESSMENT OF CANCER DRUG PRICES IN USA, THE UK AND ISRAEL	Noa Gordon	Ben-Gurion University of the Negev
PCN8	REAL-WORLD OUTCOMES OF NOVEL TREATMENTS IN PATIENTS WITH ADVANCED MELANOMA IN THE NETHERLANDS	B. Leeneman	Erasmus University Rotterdam
PCN85	COST-MINIMIZATION ANALYSIS OF LIPEGFILGRASTIM IN PROPHYLAXIS OF FEBRILE NEUTROPENIA IN CANCER PATIENTS	Dzhumber Ugrehelidze	I.M. Sechenov First Moscow State Medical University

**RESEARCH POSTER PRESENTATIONS - SESSION V: 8:45 - 13:45  
MEDICAL DEVICE/DIAGNOSTICS**

PMD112	SYSTEMATIC REVIEW OF THE VALUE OF SAFETY-ENGINEERED DEVICES IN REDUCING NEEDLESTICK AND SHARPS INJURIES	Yang Shang	Shenyang Pharmaceutical University
PMD122	A NEW ACCELERATED EARLY ACCESS PROCESS FOR DIAGNOSTICS IN FRANCE	Eve Hanna	Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université
PMD2	IMPLEMENTATION OF ONE STOP DIAGNOSIS IN PATIENTS WITH THYROID NODULES: IMPACT ON COST AND SURGERY	Marguerite Kandel	Gustave Roussy
PMD50	COST-BENEFIT ANALYSIS OF DENTAL PROSTHESIS IN UKRAINE	Sofiya-Roksolana Got	Danylo Halytsky Lviv National Medical University
PMD54	COST - EFFECTIVENESS ANALYSIS OF PRESEPSIN COMPARED WITH C-REACTIVE PROTEIN AND PROCALCITONIN IN DETECTING SEVERE BACTERIAL INFECTION IN CHILDREN AGED 29 DAYS TO 36 MONTHS OLD WITH FEVER WITHOUT SOURCE	Jennifer Amastha	Universidad del Norte
PMD57	THE COST-EFFECTIVENESS OF WHOLE-EXOME SEQUENCING IN COMPLEX PAEDIATRIC NEUROLOGY	Kjm van Nimwegen	Radboud university medical center

PMD62	COST-EFFECTIVENESS ANALYSIS OF TELEMONITORING IN GYNAECOLOGY AND OBSTETRICS	Ondřej Gajdoš	Czech Technical University in Prague
PMD68	COST-EFFECTIVENESS ANALYSIS OF SERUM FREE LIGHT CHAIN ASSAY (FREELITE®) FOR THE DIAGNOSIS OF MONOCLONAL GAMMOPATHY IN THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS	Bruno Salgado Riveros	Federal University of Parana
PMD8	ASSESSMENT OF PET/CT USE IN RADIOTHERAPY PLANNING VERSUS CT SCANS USE ONLY	Silvie Jerabkova	University of Economics, Prague